Sofroniadou Sofia, Revela Ioanna, Kouloubinis Alexandros, Makriniotou Ioanna, Zerbala Sinodi, Smirloglou Despina, Kalocheretis Petros, Drouzas Apostolos, Samonis George, Iatrou Christos
Center for Nephrology «G.Papadakis», General Hospital of Nikea-Piraeus, Piraeus/Athens, Greece.
2nd Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.
Hemodial Int. 2017 Oct;21(4):498-506. doi: 10.1111/hdi.12524. Epub 2017 Jan 11.
Ethanol lock solution has been mainly administered in paediatric and home parenteral nutrition patients in order to prevent catheter related blood stream infections (CRBSI). Its utility in hemodialysis (HD) patients with non-tunneled-uncuffed catheter (NTC) has been poorly explored.
We conducted a prospective randomized study in chronic HD patients requiring a newly inserted NTC-while awaiting for the maturation of an already established arteriovenous fistula (AVF) or arteriovenous graft (AVG) or tunneled-cuffed catheter insertion. Patients were randomized in two groups: Group A, where the lock solution was ethanol 70% + unfractionated heparin 2000 U/mL and group B, that received only unfractionated heparin 2000 U/mL. Primary end point was CRBSIs whereas exit site infections, thrombotic and bleeding episodes were the secondary end points.
One hundred three HD patients were enrolled in the study (group A, n = 52; group B, n = 51). The median number of catheter days was 32 for group A (range: 23-39) and 34 (range: 27-40) for group B with no statistically significant difference between the two groups. Group A (ethanol + heparin) demonstrated 4/52 episodes (7.69%) of CRBSI whereas Group B (heparin) 11/51 episodes (21.57%) (P = 0.04). CRBSI rates per 1000 catheter days were 2.53/1000 catheter days for group A and 6.7/1000 catheter days for group B (P = 0.04). Mean cumulative infection-free catheter survival in the ethanol group did not differ significantly compared to the heparin group (log-rank test = 2.99, P = 0.08). Thrombotic episodes did not differ between the two groups.
Locking of NTCs in HD patients with ethanol 70% + unfractionated heparin reduces CRBSI rates without increasing the thrombotic episodes.
乙醇封管溶液主要用于儿科和家庭肠外营养患者,以预防导管相关血流感染(CRBSI)。其在非隧道无袖套导管(NTC)的血液透析(HD)患者中的应用尚未得到充分研究。
我们对需要新插入NTC的慢性HD患者进行了一项前瞻性随机研究,这些患者正在等待已建立的动静脉内瘘(AVF)或动静脉移植物(AVG)成熟,或等待隧道式带袖套导管插入。患者被随机分为两组:A组,封管溶液为70%乙醇+2000 U/mL普通肝素;B组,仅接受2000 U/mL普通肝素。主要终点是CRBSI,而出口部位感染、血栓形成和出血事件是次要终点。
103例HD患者纳入研究(A组,n = 52;B组,n = 51)。A组导管留置天数中位数为32天(范围:23 - 39天),B组为34天(范围:27 - 40天),两组之间无统计学显著差异。A组(乙醇+肝素)发生4/52例(7.69%)CRBSI,而B组(肝素)为11/51例(21.57%)(P = 0.04)。每1000导管日的CRBSI发生率,A组为2.53/1000导管日,B组为6.7/1000导管日(P = 0.04)。乙醇组的平均累积无感染导管存活时间与肝素组相比无显著差异(对数秩检验=2.99,P = 0.08)。两组之间血栓形成事件无差异。
在HD患者中,用70%乙醇+普通肝素封管NTC可降低CRBSI发生率,且不增加血栓形成事件。